Results 11 to 20 of about 112,813 (257)

von Willebrand factor binds to the surface of dendritic cells and modulates peptide presentation of factor VIII

Haematologica, 2016
It has been proposed that von Willebrand factor might affect factor VIII immunogenicity by reducing factor VIII uptake by antigen presenting cells. Here we investigate the interaction of recombinant von Willebrand factor with immature monocyte-derived ...
Nicoletta Sorvillo, Robin B. Hartholt, Esther Bloem, Magdalena Sedek, Anja ten Brinke, Carmen van der Zwaan, Floris P. van Alphen, Alexander B. Meijer, Jan Voorberg   +8 more
doaj   +1 more source

Removal of Mannose-Ending Glycan at Asn2118 Abrogates FVIII Presentation by Human Monocyte-Derived Dendritic Cells

Frontiers in Immunology, 2020
The development of an immune response against therapeutic factor VIII is the major complication in hemophilia A patients. Oligomannose carbohydrates at N239 and/or N2118 on factor VIII allow its binding to the macrophage mannose receptor expressed on ...
Sandrine Delignat, Julie Rayes, Suryasarathi Dasgupta, Bagirath Gangadharan, Cécile V. Denis, Olivier D. Christophe, Jagadeesh Bayry, Srinivas V. Kaveri, Sébastien Lacroix-Desmazes   +8 more
doaj   +1 more source

Acquired Factor VIII Deficiency Presenting as Gross Hematuria in a Hispanic, Pregnant Patient with Previously Undiagnosed Connective Tissue Disease

Case Reports in Rheumatology, 2021
Acquired factor VIII deficiency is a bleeding disorder caused by the presence of autoantibodies against clotting factor VIII. We report a case of a 24-year-old pregnant woman who presented with gross hematuria secondary to acquired factor VIII deficiency
Christine Loftis, Emilia C. Dulgheru, Rosa White   +2 more
doaj   +1 more source

Calcium Prevents Enhanced Degradation of Factor VIII in the Condition of Motion

Biology, 2023
Background: Hemophilia A and B induce recurrent bleeding episodes, mainly in skeletal muscles and joints that are in intermittent motion. We have previously demonstrated that intermittent motion contributes to increased degradation of factors VIII and IX.
Haim Cohen, Anat Keren-Politansky, Yonatan Crispel, Chen Yanovich, Keren Asayag, Yona Nadir   +5 more
doaj   +1 more source

Identification of Key Coagulation Activity Determining Elements in Canine Factor VIII

Molecular Therapy: Methods & Clinical Development, 2020
It is well known that canine factor VIII (cFVIII) has a higher specific activity than does human FVIII (hFVIII), and it has been previously demonstrated that cFVIII light chain is able to enhance hFVIII activity.
Jenni Firrman, Qizhao Wang, Wenman Wu, Biao Dong, Wenjing Cao, Andrea Rossi Moore, Sean Roberts, Barbara A. Konkle, Carol Miao, LinShu Liu, Dong Li, Weidong Xiao   +11 more
doaj   +1 more source

Recombinant porcine factor VIII: Lessons from the past and place in the management of hemophilia A with inhibitors in 2021

Research and Practice in Thrombosis and Haemostasis, 2021
The most serious complication of factor VIII (FVIII) replacement therapy is the occurrence of anti‐FVIII alloantibodies that can strongly reduce or abolish the effect of human FVIII products.
Yesim Dargaud, Carmen Escuriola‐Ettingshausen   +1 more
doaj   +1 more source

Pathogenic immune response to therapeutic factor VIII: exacerbated response or failed induction of tolerance?

Haematologica, 2019
Therapeutic factor VIII is highly immunogenic. Despite intensive research in the last decades, the reasons why 5-30% of patients with hemophilia A (of all severities) develop inhibitory anti-factor VIII antibodies (inhibitors) following replacement ...
Aditi Varthaman, Sébastien Lacroix-Desmazes   +1 more
doaj   +1 more source

Extrahepatic sources of factor VIII potentially contribute to the coagulation cascade correcting the bleeding phenotype of mice with hemophilia A

Haematologica, 2015
A large fraction of factor VIII in blood originates from liver sinusoidal endothelial cells although extrahepatic sources also contribute to plasma factor VIII levels.
Diego Zanolini, Simone Merlin, Maria Feola, Gabriella Ranaldo, Angela Amoruso, Gianluca Gaidano, Mauro Zaffaroni, Alessandro Ferrero, Sandra Brunelleschi, Guido Valente, Sanjeev Gupta, Maria Prat, Antonia Follenzi   +12 more
doaj   +1 more source

Impact of being underweight or overweight on factor VIII dosing in hemophilia A patients

Haematologica, 2013
Since 1981, the number of factor VIII units to infuse into patients with hemophilia A in order to achieve adequate circulating factor VIII levels has been calculated using the formula: [body weight(kg)×desired factor VIII increase(%)]/2, assuming a ...
Séverine Henrard, Niko Speybroeck, Cedric Hermans   +2 more
doaj   +1 more source

Modelling US health equity impacts of emicizumab for severe haemophilia A: aggregate distributional cost-effectiveness analysis

BMJ Open
Objectives Emicizumab is the first bispecific antibody approved for prophylaxis in people with haemophilia A with or without factor VIII inhibitors. Aggregate distributional cost-effectiveness analysis assesses health equity impacts by evaluating how ...
Randall Curtis, Thomas Majda, Janet S. Lee, Stacey L. Kowal   +3 more
doaj   +1 more source